OvaScience Announces Closing of Public Offering of Common Stock

WALTHAM, Mass.–(BUSINESS WIRE)–OvaScienceSM (NASDAQ: OVAS), a global fertility company
focused on the discovery, development and commercialization of new
treatment options, today announced the closing of its previously
announced public offering, including the exercise in full by the
underwriters of their option to purchase an additional 1,072,500 shares
of common stock at the public offering price of $7.00 per share. The
exercise of the underwriters’ option brought the total number of shares
of common stock sold by OvaScience to 8,222,500 shares and increased the
total net proceeds raised in this offering to $53.8 million, after
deducting underwriting discounts and commissions and estimated expenses.
OvaScience intends to use the proceeds from this offering to fund the
commercial expansion of the AUGMENTSM treatment in its key
regions, Japan and Canada, the ongoing pre-commercial activities for the
OvaPrimeSM treatment and the OvaTureSM treatment,
and working capital and other general corporate purposes.

Leerink Partners LLC acted as sole book runner for the offering.
Oppenheimer & Co. Inc., H.C. Wainwright & Co., Roth Capital Partners,
LLC and JonesTrading Institutional Services LLC acted as co-managers of
the offering.

The public offering of common stock was made pursuant to a shelf
registration statement on Form S-3 that was previously filed with and
declared effective by the Securities and Exchange Commission (“SEC”). A
final prospectus supplement relating to and describing the terms of the
offering has been filed with the SEC. Copies of the final prospectus and
accompanying prospectus relating to the offering, when available, may be
obtained from Leerink Partners LLC; Attention: Syndicate Department; One
Federal Street; 37th Floor; Boston, MA, 02110, or by phone at
1-800-808-7525, ext. 6142, or by email at syndicate@leerink.com.

This press release shall not constitute an offer to sell or a
solicitation of an offer to buy, nor shall there be any sale of these
securities in any state or jurisdiction in which such an offer,
solicitation or sale would be unlawful prior to registration or
qualification under the securities laws of any such state or

About OvaScience

OvaScience, Inc. (NASDAQ: OVAS) is a global fertility company dedicated
to improving treatment options for women around the world. OvaScience is
discovering, developing and commercializing new fertility treatments
because it believes women deserve more options. Each OvaScience
treatment is based on the Company’s proprietary technology platform that
leverages the breakthrough discovery of egg precursor (EggPCSM)
cells – immature egg cells found inside the protective ovarian lining.
The AUGMENTSM treatment, a fertility option specifically
designed to improve egg health, is available in certain IVF clinics in
select international regions. OvaScience has commenced a non-commercial
preceptorship training program with the OvaPrimeSM treatment,
which could increase a woman’s egg reserve, and is developing the OvaTureSM treatment,
a potential next-generation IVF treatment that could help a woman
produce healthy, young, fertilizable eggs without hormone injections.
OvaScience treatments are not available in the U.S.

Forward-Looking Statements

This press release includes forward-looking statements including
statements about OvaScience’s intended use of proceeds from the public
offering. Actual results may differ materially from those indicated by
these forward-looking statements as a result of various important
factors, including risks related to:
the possibility that
international IVF clinics that OvaScience works with may determine not
to provide or continue providing or studying the AUGMENT treatment or
OvaPrime treatment, or to delay providing such treatments, based on
clinical efficacy, safety or commercial, logistic, regulatory,
enrollment, inability to agree on commercial terms, or other reasons;
the science underlying the company’s treatments (including the AUGMENT,
OvaPrime and OvaTure treatments), which is unproven; the Company’s
ability to obtain regulatory approval or licenses where necessary for
its treatments; OvaScience’s ability to develop its treatments on the
timelines it expects, if at all; the Company’s ability to commercialize
its treatments, on the timelines it expects, if at all; as well as those
risks more fully discussed in the “Risk Factors” section of its most
recently filed Annual Report on Form 10-K and Quarterly Reports on Form
10-Q. The forward-looking statements contained in this press release
reflect the Company’s current views with respect to future events. It
anticipates that subsequent events and developments will cause its views
to change. However, while it may elect to update these forward-looking
statements in the future, it specifically disclaims any obligation to do
so. These forward-looking statements should not be relied upon as
representing OvaScience’s view as of any date subsequent to the date

## ## ##


Rebecca J. Peterson, 617-420-8736